Scott Hauenstein - Concepedia

Author

Scott Hauenstein

Prometheus Biosciences (United States)

Also Known As

S. Hauenstein, Scott Hauenstein, Scott I. Hauenstein

Publications

Citations

H-Index

Concepts

All Affiliations

Prometheus Biosciences (United States)KU Leuven University of California, Santa Barbara Thomas Jefferson University Western University

About

Scott Hauenstein is an author at Prometheus Biosciences (United States) specializing in medicine, immunology, and autoimmune disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	689
2	Natural Sciences	3	3	158
3	Allergy	3	3	241
4	Biochemistry	2	2	69
5	Chemical Biology	1	1	39

Scott Hauenstein

Publications

Citations

H-Index

Page 1

	Year	Citations
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient Niels Vande Casteele, Ann Gils, Sharat Singh, The American Journal of Gastroenterology	2013	342
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease Niels Vande Casteele, Reena Khanna, Barrett G. Levesque, Gut	2014	283
Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum Shui-Long Wang, Linda Ohrmund, Scott Hauenstein, Journal of Immunological Methods	2012	203
Concentrations of 6-Thioguanine Nucleotide Correlate With Trough Levels of Infliximab in Patients With Inflammatory Bowel Disease on Combination Therapy Andrés Yarur, Maddie Kubiliun, Frank Czul, Clinical Gastroenterology and Hepatology InflammationTrough LevelsAnti-inflammatoryMedicineImmunology	2015	157
Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy Filip Baert, David Drobne, Ann Gils, Clinical Gastroenterology and Hepatology Trough LevelsAutoimmune DiseaseAllergyInfliximab Predict SafetyImmunology	2014	134
Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohnʼs Disease and Ulcerative Colitis Andrés Yarur, Anjali Jain, Scott Hauenstein, Inflammatory Bowel Diseases	2016	111
A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease Barrett G. Levesque, Gordon R. Greenberg, Guangyong Zou, Alimentary Pharmacology & Therapeutics	2014	100
Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial Filip Baert, Venkateswarlu Kondragunta, Steven Lockton, Gut	2015	94
Shape-selective RNA recognition by cysteinyl-tRNA synthetase Scott Hauenstein, Chunmei Zhang, Ya‐Ming Hou, Nature Structural & Molecular Biology MedicineNatural SciencesRna Structure PredictionRna BiologyMolecular Biology	2004	89
Long-Term Outcome of Patients With Crohn’s Disease Who Discontinued Infliximab Therapy Upon Clinical Remission Konstantinos Papamichael, Niels Vande Casteele, Ann Gils, Clinical Gastroenterology and Hepatology Anti-inflammatoryGastroenterologyLong-term OutcomeMedicineInflammatory Disease	2014	81

Page 1